List of Uceris drug patents

Uceris is owned by Salix.

Uceris contains Budesonide.

Uceris has a total of 5 drug patents out of which 0 drug patents have expired.

Uceris was authorised for market use on 14 January, 2013.

Uceris is available in tablet, extended release;oral dosage forms.

Uceris can be used as induction of remission in patients with active, mild to moderate ulcerative colitis.

The generics of Uceris are possible to be released after 07 September, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192581 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(8 years from now)

US8895064 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(8 years from now)

US10660858 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(8 years from now)

US9132093 SALIX Controlled release and taste making oral pharmaceutical composition
Sep, 2031

(8 years from now)

US10307375 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(8 years from now)

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 14 January, 2013

Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of UCERIS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in